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SHP-2 (PTPN11), a ubiquitously expressed protein tyrosine phosphatase, is critical for hematopoietic cell development and
function owing to its essentialrole in growth factor/cytokine signaling.More importantly, germline and somaticmutations in this
phosphataseare associated with Noonansyndrome, Leopard syndrome, and childhood hematologic malignancies.The molecular
mechanismsbywhichSHP-2mutationsinducethesediseasesarenotfullyunderstood,asthebiochemicalbasesofSHP-2functions
still remain elusive. Further understanding SHP-2 signaling activities and identiﬁcation of its interacting proteins/substrates will
shed light on the pathogenesis of PTPN11-associated hematologicmalignancies,which, in turn, maylead to novel therapeutics for
these diseases.
1.Introduction
SHP-2, encoded by PTPN11, is a ubiquitously expressed
protein tyrosine phosphatase (PTP) that contains two
tandem Src homology 2 (SH2) domains, a PTP domain,
and a C-terminal tail with tyrosyl phosphorylation sites
and a prolyl-rich motif [1–5]. It shares a similar overall
structure and high homology with SHP-1, another SH2
domain-containing PTP that is predominantly expressed
in hematopoietic cells [6, 7]. However, SHP-2 and SHP-1
play opposing roles in hematopoietic cell function [8–10].
Genetic analyses using the Xenopus model have revealed that
both the SH2 domains and the PTP domains contribute
to their signaling and thus functional speciﬁcities [11, 12].
The 2.0 ˚ A X-ray crystal structure of SHP-2 reveals that the
protein is self-inhibited by the binding of the N-terminal
SH2 (N-SH2) domain to the PTP domain via hydrogen
bonds [13, 14]. Upon growth factor/cytokine stimulation,
binding of SHP-2 via its SH2 domains to phosphorylated
tyrosine residues on growth factor receptors or docking
proteins results in disruption of the autoinhibitory interac-
tion, leading to exposure of the catalytic site and enzymatic
activation [13, 14]. Remarkably, mutations in PTPN11 have
been identiﬁed in several human diseases, such as the
developmental disorders Noonan syndrome (NS) [15]a n d
Leopard syndrome (LS) [16, 17], childhood hematologic
malignancies [18–20], and sporadic solid tumors [21]. Most
of these disease-associated mutations aﬀect N-SH2 or PTP
domain residues involved in the basal inhibition, resulting
in either “activated mutants” or “inactivated mutants” of
SHP-2. Although signiﬁcant progress has been made in the
past years,signalingmechanisms ofSHP-2andthemolecular
mechanisms by which SHP-2 mutations are associated with
human diseases are still not fully understood. Emerging
evidence has indicated that SHP-2 may also have important
functions in the nucleus and the mitochondria [22–24].
Better understanding the role of SHP-2 in these organelles
may provide new insights into the pathogenesis of SHP-
2 mutation-associated human diseases. This paper focuses
on the physiological and pathological roles of SHP-2 in
hematopoietic cell development and leukemogenesis.
2.SHP-2inCytoplasmicSignal Transduction
SHP-2 is primarily localized to the cytosol and has been
implicated in cell signaling initiated by growth factors,2 Journal of Signal Transduction
cytokines, and hormones, regulating cell survival/growth
and diﬀerentiation [8, 25]. In addition, SHP-2 modulates
cell adhesion molecules-induced signal transduction and has
been found to play an important role in cell migration
and motility [26–30]. This phosphatase plays complicated
roles in cell signaling processes. It is involved in a variety
of cell signaling cascades, such as the RAS-MAP kinase,
JAK-STAT, PI3K-AKT, Rho, NF-κB, and NFAT pathways
[8, 25]. Furthermore, it acts at multiple sites in individual
pathways. SHP-2 appears to functionin cell signaling in both
catalytic-dependent and -independent manners. While its
catalytic activity is important for cell signaling, SHP-2 can
also function as an adaptor independent of catalytic activity
[31–33]. Despite extensive studies over the past decade, the
mechanisms of SHP-2 action are still poorly deﬁned. SHP-2
interacts with a number of cell signaling components, such
as growth factor/cytokine receptors, SIRPα/SHPS-1, PZR,
Grb2, FRS, IRS-1, Gab1, Gab2, p85, STAT5/3/1, and Sprouty
[8, 25]. Of these partners, some are the targets of SHP-2
enzymatic activity. However, none of the putative substrates
identiﬁed to date can fully account for the signaling eﬀects
of SHP-2 on the many biological processes with which it
has been implicated. PTPs were originally thought to be
negative regulators owing to their opposite roles to protein-
tyrosine kinases (PTKs). However, SHP-2 is a PTP that plays
an overall positive role in many cell-signaling processes, in
particular, the RAS-ERK pathway, promoting cell growth
and diﬀerentiation. The underlying mechanisms remain
elusive. In most cases, SHP-2 is considered to regulate an
upstream element necessary for RAS activation; yet, SHP-
2 functions downstream of, or parallel to, RAS activation
have also been demonstrated [34]. The PTP activity of
SHP-2 has been shown to be required for full activa-
tion of RAS. Three possibilities have been proposed [35].
First, SHP-2 promotes RAS activation by dephosphorylating
tyrosine-phosphorylated sites of receptor PTKs or docking
proteins that bind p120 RAS-GTPase activating protein
(RAS-GAP), a negative regulator of RAS activity; second,
SHP-2 potentiates activation of Src family kinases (SFKs)
by dephosphorylating Csk (a negative regulator of SFKs)
binding protein (Cbp), thereby preventing access of Csk to
S F K s .E n h a n c e da c t i v a t i o no fS F K si nt u r nl e a d st oo p t i m a l
RAS activation; ﬁnally, SHP-2 promotes RAS activation by
dephosphorylating Sprouty, another negative regulator of
RAS.Althoughinmost circumstances,SHP-2playsapositive
role in transducing signals relayed from receptor PTKs,
SHP-2 can also function as a negative regulator depending
upon stimuli, binding partners, and interacting downstream
signaling networks [36]. For example, it negatively regulates
JAK/STAT signaling initiated by interferon-α and -γ [37].
Another prominent example is that SHP-2 negatively regu-
lates gp130 signaling triggered by leukemia inhibitory factor,
ciliary neurotrophic factor, and interleukin-6 (IL-6) [38, 39].
3.SHP-2inthe Nucleusand theMitochondria
Emerging evidence shows that SHP-2 is distributed to the
nucleus and the mitochondria, where it can also have impor-
tant functions [22–24]. Prolactin stimulation of mammary
cells leads to the nuclear translocation of SHP-2 as a
complex with STAT5 which then binds to DNAand regulates
transcription of milk protein genes [22]. Also, it has been
demonstrated that nuclear SHP-2 dephosphorylates STAT1
and STAT3 at tyrosine and serine residues and thus inhibits
their transcriptional activities [40, 41]. Recently, SHP-2 has
been found to inhibit nuclear export of telomerase reverse
transcriptase (TERT), the catalytic subunit of telomerase,
in the nucleus by dephosphorylating Tyrosine707 of TERT,
thereby enhancing nuclear telomerase activity [42]. Since
telomerase plays an important role in maintaining telomere
length and shortening of telomeres has been linked to
chromosomal instability and cell aging, SHP-2 may thus be
involved in the regulation of aging processes. Our previous
studies showed that about 30%–40% of SHP-2 is localized
to the nucleus in mouse embryonic ﬁbroblasts and that
SHP-2 plays an important role in DNA damage-induced
cellular responses [23]. SHP-2 promotes DNA damage-
induced apoptosis by enhancing the c-Abl kinase-mediated
pathway [23]. It is also required for DNA damage-induced
translocation of Cdc25C from the nucleus to the cytoplasm
[43]. Loss of functional SHP-2 decreases DNA damage-
inducedapoptosisaswell asthecell-cyclecheckpoint(G2/M)
response [23, 43]. Using “rescue” approaches, we have
deﬁnedthat SHP-2functions inDNAdamage-induced c-Abl
activation, and thereby apoptosis, in a catalytic-dependent
manner, whereas its role in the DNA damage-induced G2/M
checkpoint does not require catalytic activity [44].
SHP-2isalsodistributedtothemitochondria,speciﬁcally
the intercristae/intermembrane space (IMS) [24, 45]. How-
ever, the role of SHP-2 in the mitochondria remains unclear.
The mitochondrial oxidative phosphorylation (OxPhos)
system provides the vast majority of cellular energy and
produces reactive oxygen species (ROS). Recently, Lee et al.
propose that OxPhos complexes might be direct or indirect
targets of SHP-2 [46]. They have found that cytochrome c
oxidase (CcO) activity and ROS levels are signiﬁcantly
increased, whereas mitochondrial membrane potential and
ATP content are decreased in constitutively active SHP-2
mutant cells. CcO subunit II can be phosphorylated by
Src kinase which is also localized to the IMS [47, 48]. As
it has long been recognized that cytosolic SHP-2 and Src
regulate each other, their observations raise the possibility
that SHP-2 enhances CcO activity in the mitochondria by
activating Src kinase. However, other signaling pathways
may also be aﬀected by mitochondrial SHP-2. Identiﬁcation
of mitochondrial substrate(s) and downstream target(s) of
SHP-2willshed lightonthemolecularmechanisms bywhich




Hematopoiesis is the cellular process in which all types
of blood cells including erythroid, myeloid, and lymphoid
cells are produced from pluripotent hematopoietic stem
cells (HSCs). It is tightly controlled by environmental
cues, such as cytokines and growth factors. DysregulationJournal of Signal Transduction 3
of cytokine/growth factor signaling can result in blood
disorders, including hematologic malignancies. SHP-2 is
highly expressed in hematopoieticcells. Ourpreviousstudies
havedemonstratedthatincontrasttothehighlyrelatedSHP-
1 phosphatase which negatively regulates hematopoietic cell
development [49, 50], SHP-2 plays an overall positive role
in hematopoiesis [51–53]. N-SH2 deletion generates a loss
of function mutation in SHP-2. This mutation severely
suppresses the development of erythroid and myeloid pro-
genitors in homozygous mutant embryos [51]. Consistent
with this result, neither erythroid nor myeloid progenitors
derived from mutant embryonic stem (ES) cells with the
N - S H 2d e l e t i o nm u t a t i o ni nS H P - 2w e r ed e t e c t a b l ei nt h e
fetal liver or bone marrow of the chimeric animals generated
from these ES cells [52]. In addition, SHP-2 is required
for lymphopoiesis [53]. In Rag2-deﬁcient blastocyst rescue
experiments, diﬀerentiation of lymphoid lineages from ES
cells with the N-SH2 deletion mutation of SHP-2 was
blocked before pro-T- and pro-B-cell stages [53]. These data
suggest that SHP-2 is required for the development of all
blood cell lineages. Recent studies have demonstrated that
SHP-2 plays a critical role in the survival and maintenance of
HSCs. Even heterozygous N-SH2 deletion mutation in SHP-
2 causes the HSC pool to reside in a less quiescent (G0)s t a t e .
HSC repopulating capacity and self-renewal are markedly
reduced by this mutation [54]. Furthermore, depletion
of SHP-2 from hematopoietic cells in SHP-2 conditional
knockout mice results in rapid loss of HSCs and immature
progenitors of all hematopoietic lineages in a gene dosage-
dependent and cell-autonomous manner [55].
The signaling mechanisms by which SHP-2 regulates
hematopoietic cell development and function are not well
understood. SHP-2 participates in the signal transduction
of many hematopoietic cytokines, such as IL-3, IL-5, IL-
6, IL-9, IL-11, EPO, SCF, GM-CSF, M-CSF, and Flt3-ligand
[9]. SHP-2 appears to promote hematopoietic cell develop-
ment by positively regulating critical signaling processes of
hematopoietic growth factors/cytokines. We have demon-
strated that SHP-2 is required for the signal transduction
of IL-3, a cytokine involved in hematopoietic cell survival,
proliferation, and diﬀerentiation [33]. IL-3-induced activa-
tionofJAK/STAT,ERK,and PI3Kpathwaysinhematopoietic
cells with N-SH2 deletion mutation of SHP-2 was impaired
[33]. However, in catalytically deﬁcient SHP-2 C459S-
overexpressing cells, IL-3-induced PI3K activation remained
unaltered, while activation of JAK2 and ERK was reduced
[33]. These observations suggest that SHP-2 plays multiple
roles in IL-3 signal transduction, acting in both catalytic-
dependent and -independent manners in the JAK/STAT,
ERK, and PI3K pathways (Figure 1). Interestingly, SHP-2
also has a negative eﬀect on hematopoietic cell survival.
Overexpression of wild-type SHP-2 in hematopoietic cells
compromised their hematopoietic activities and enhanced
cytokine deprivation-induced apoptosis by dephosphorylat-
ing STAT5 [56].
SHP-2 also plays an important role in the regulation
of the immune system through its eﬀects on cytokine and
inhibitory receptor signaling pathways [57]. In addition to
its well-established role in cytokine responses, SHP-2 has
been implicated as an important mediator of inhibitory
receptor signaling. Inhibitory receptors contain one or more
immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
within their cytoplasmic domains essential for generation
and transduction of inhibitory signals. Tyrosine phosphory-
lation oftheITIM allowsittobindand activate phosphatases
containing SH2 domains. SHP-2 has been found to be
recruited to several inhibitory receptors, including the T-
lymphocyte-associated antigen 4 (CTLA-4), programmed
death-1 (PD-1), B- and T-lymphocyte attenuator (BTLA),
killer cell Ig-like receptors (KIRs), CD31 in lymphocytes,
and ITIM-containing receptors in granulocytes and platelets
[57]. The role of SHP-2 in T cells is still controversial.
Frearson and Alexander [58] showed that SHP-2 played a
positive role in T cell receptor (TCR) signaling. Expression
of catalytically deﬁcient SHP-2 C459S signiﬁcantly inhibited
TCR-induced activation of ERK, but had no eﬀect on TCR-
zeta chain tyrosine phosphorylation or TCR-elicited Ca2+
transients. However, another study implicates SHP-2 as a
negative regulator in TCR signaling [59]. Overexpression
of Gab2, a critical downstream substrate/target of SHP-
2, in T cells resulted in downregulation of TCR-mediated
NFAT activation and IL-2 production [59]. Gab2 mutants
lacking SHP-2-binding sites abrogated the inhibitory activity
of Gab2, but its inhibitory function was restored by fusing
to active SHP-2 as a chimeric protein, suggesting that the
inhibitory function of Gab2 is largely dependent on SHP-2
[59]. Additionally, SHP-2 might be involved in the downreg-
ulation of T-cell adhesion processes [60]. TCR-induced ROS
production selectively inhibits SHP-2-mediated dephospho-
rylation of Vav1 and ADAP associated with SLP-76, which
limitsTCR-inducedadhesion andintegrin clustering[60].In
consistent, overexpression of SHP-2 C459S enhanced TCR-
induced LFA-1 clustering and the adhesion of Jurkat T cells
to ﬁbronectin [60].
Recent mouse studies have provided new insights into
the role of SHP-2 in immune responses. Transgenic mice
with expression of dominant-negative SHP-2 C459S in T
cells have normal T cell development but display increased
Tc e l la c t i v a t i o nin vivo, and aged mice have elevated serum
antibodies [61]. In addition, phosphorylation of the adaptor
LAT (linker for activation of T cells) downstream of TCR
stimulation is defective in SHP-2 C459S T cells, whereas
SHP-2 C459S-expression does not aﬀect the majority of
TCR-inducedtyrosine phosphorylation, ERKactivation, and
TCR-driven proliferation [61]. These results suggest that
wild-type SHP-2 plays an important role in suppressing the
diﬀerentiation of T cells to a Th2 phenotype. Considering
that overall TCR response is unchanged in SHP-2 C459S-
expressing mice, it is likely that the phenotypes observed in
the SHP-2 C459S transgenic mice may not be due to direct
eﬀects of SHP-2 on TCR-mediated signaling but rather on
signaling pathways downstream of other receptors. However,
this conclusion was challenged by more recent studies with
selective SHP-2 depletion in thymocytes [62]. Lck-Cre-
mediated deletion of SHP-2 in the thymus resulted in a
signiﬁcant block in thymocyte diﬀerentiation/proliferation
and reduced expansion of CD4+ T cells. Furthermore, SHP-
2-depleted mature T cells showed decreased TCR signaling4 Journal of Signal Transduction
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Figure 1: Catalytic-dependent and -independent roles of SHP-2 in IL-3/GM-CSF signaling.
in vitro. These data supports that SHP-2 is a common




Notably, germline mutations in PTPN11 (SHP-2) are found
in ∼50% of the cases with the developmental disorder NS
[15] and nearly all patients of the developmental disorder
LS that shares certain features with NS [16, 17]. Moreover,
somatic mutations in PTPN11 occur in about 35% of the
patients with juvenile myelomonocytic leukemia (JMML)
[18, 19], a childhood myeloproliferative disorder (MPD).
In addition, PTPN11 mutations have been identiﬁed in
pediatric acute leukemias, such as myelodysplastic syndrome
(MDS) (10%) [18, 19], B cell acute lymphoblastic leukemia
(B-ALL) (7%) [20, 63] ,a n da c u t em y e l o i dl e u k e m i a( A M L )
(4%) [64]. In contrast, PTPN11 mutations occur rarely in
adult patients with MDS, AML, or chronic myelomonocytic
leukemia (CMML) [65–67]. The reason for this is unclear.
PTPN11 mutations found in NS and LS are clustered in
the PTP domain, whereas most of the leukemia-associated
PTPN11mutationsarelocatedintheN-SH2domain.NSand
leukemia mutations cause changes in amino acids located at
the interface formed by the N-SH2 and PTP domains in the
self-inhibited SHP-2conformation,disruptingtheinhibitory
intramolecular interaction, leading to hyperactivation of the
catalytic activity [18]. Biochemical analyses have shown that
SHP-2 mutants found in leukemias are more enzymatically
active than those in NS [18, 68], suggesting that low levels
of SHP-2 activation result in NS, whereas higher levels of
SHP-2 activity may be required for leukemogenesis. PTPN11
mutations found in LS are located in the PTP domain,
also causing changes in amino acids located at the interface
formed by the N-SH2 and PTP domains and disrupting the
intramolecular interaction. However, these mutations result
in inactivation of the enzymatic activity due to the changes
in keycatalyticamino acid residues in the phosphatase active
site [69].
Recent studies have begun to elucidate the pathogene-
sis of PTPN11 mutation-associated diseases. Heterozygous
PTPN11 D61G and PTPN11 Y279C knock-in mice develop
NS, and LS phenotypes, respectively, strongly suggesting a
causal role of PTPN11 D61G and PTPN11 Y279C mutations
in the pathogenesis of these two diseases [70, 71]. Moreover,
PTPN11D61G/+ mice develop moderate MPD, characterized
by excessive myeloid cell expansion and hepatosplenomegaly
[70]. Myeloid progenitors from these mutant mice are
hypersensitive to cytokines (GM-CSF and IL-3), reminiscent
of JMML, the hallmark of which is the hypersensitive
pattern of myeloid progenitor colony growth in response
to GM-CSF [72]. Our recent studies showed that GM-
CSF and IL-3-induced ERK and AKT activation was
enhanced inPTPN11D61G/+ macrophagesand mast cells[73].
Clearly, aberrantly enhanced cytokine signaling contributes
to the excess expansion of myeloid cells in these mutant
animals. More importantly, PTPN11D61G/+ mutation also
aberrantly activates HSCs. This mutation accelerates HSC
cycling, thereby increasing the stem cell pool and elevating
short-term and long-term repopulating capabilities [73].
Inducible knock-in mice expressing the leukemogenic allele
PTPN11D61Y in hematopoietic cells develop fatal MPD [74].
PTPN11D61Y/+ mutation decreases the HSC pool and the
percentageofHSCsinG0 phasein thebonemarrow, whereas
the number of HSCs was markedly increased and larger
proportion of HSCs are quiescent in the spleen [74]. These
data suggests PTPN11D61Y/+ mutation drives HSCs in the
bone marrow out of the quiescence, and they migrate from
bone marrow to the spleen. Although global PTPN11D61G/+
mice similarly show the increased HSCs in the spleen, and
quiescent HSCs are also decreased in the bone marrow, the
overall HSCpool inPTPN11D61G/+ bonemarrow is increased
[73].SincetheD61YmutationismorepotentthantheD61G
mutation in enhancing the catalytic activity of SHP-2, the
diﬀerenceinHSCphenotypescausedby thesetwomutations
suggests that the pathogenic eﬀectsof PTPN11 mutations on
HSChomeostasisisdependentonthelevelofSHP-2catalytic
activity. In addition, stem cell microenvironments of these
two mouse models may also contribute to the diﬀerent HSCJournal of Signal Transduction 5
phenotypes. Unlike PTPN11D61Y/+ inducible knock-in mice
where the mutation is primarily within the hematopoietic
compartment, PTPN11D61G/+global knock-in mice carry the
same mutation in all tissues and cells, including endothelial,
osteoblasts, and other stromal cells that compromise the
microenvironment for HSCs. PTPN11D61G/+ mutationin the
microenvironment may exert certain detrimental eﬀects on
HSC homeostasis by altering cytokine/growth factor secre-
tion. Thus, the HSC phenotypes caused by PTPN11D61G/+
germline mutation may represent a combined eﬀect of
PTPN11 mutation in HSCs and in the microenvironment.
The molecularmechanisms by which PTPN11mutations
inducehematopoieticmalignancies are notfully understood.
Hyperactive RAS signaling is the central event in the
abnormal growth of malignant myeloid cells. Somatic RAS
point mutations are found in ∼20% of JMML [75]a n d∼
40% of CMML cases [76], and NRAS or KRAS mutations
occur in ∼20% of AML specimens [77]. Given the positive
role of SHP-2 in the RAS pathway, it is possible that PTPN11
mutations contribute to hematopoietic malignancies also by
deregulating RAS-ERK signaling. However, other signaling
pathways may also contribute to PTPN11-associated leuke-
mogenesis. Studies from our laboratory and others have
shown that leukemia-associated PTPN11 mutations also
enhance multiple other hematopoietic signaling cascades,
such as PI3K/AKT and JAK/STAT pathways [73, 74, 78,
79]. Mutant SHP-2 also has increased interactions with
Gab2, Grb2, and p85, contributing to enhanced activation of
thesepathways[78].Intriguingly,catalyticallyinactiveSHP-2
E76K with an additional C459S mutation retained the capa-
bility to increase interaction with Gab2 and to enhance acti-
vationofthePI3Kpathway,suggesting thatinadditiontothe
elevated catalytic activity, fundamental changes in physical
and functional interactions betweengain-of-function (GOF)
mutant SHP-2 and signaling partners also play an important
role in cytokine hypersensitivity. This notion is further
supported by the fact that both NS and LS are associated
with increased risk of hematologic malignancies although
PTPN11 mutations found in NS and LS activate and inacti-
vate SHP-2 enzymatic activity, respectively. It, thus, appears
thatcatalyticactivityofmutantSHP-2isnotfullyresponsible
forthepathogeniceﬀects.Rather, increasedadaptorfunction
of mutant SHP-2 also contributes to the enhanced down-
stream signaling. Consistent with this idea, LS mutations,
like NS mutations, also enhance SHP-2 binding to signaling
partners due to its protein conformational changes resulting
from the mutations [69]. It would be interesting to see
how LS mutation PTPN11 Y279C aﬀects hematopoietic cell
development in the mutation knock-in mice [71].
Other recent studies provide additional new insights
into the mechanisms by which PTPN11 mutations induce
hematologic malignancies. Konieczna et al. have found
that the eﬀect of leukemia-associated SHP-2 mutants on
myeloid cell transformation involves inactivation of inter-
feron consensus sequence-binding protein (ICSBP), which is
an interferon-regulatory transcription factor that functions
as a leukemia tumor suppressor [80]. ICSBP tyrosine phos-
phorylationduringmyelopoiesisisrequiredfortranscription
of NF1,w h i c hs u b s e q u e n t l yi n a c t i vates cytokine-activated
RAS, thereby creating a negative feedback mechanism for
cytokine-induced proliferation [81]. Consequently, dephos-
phorylation of ICSBP by constitutively active mutants of
SHP-2 inhibits ICSBP-dependent NF1 transcription, thereby
impairing this negative feedback mechanism on cytokine-
activated RAS and contributing to the proliferative phe-
notype in myeloid malignancies. In addition, the same
group reported that HoxA10, a homeodomain transcrip-
tion factor that represses myeloid diﬀerentiation genes, is
also a substrate for SHP-2. As tyrosine phosphorylation
of HoxA10 decreases its DNA-binding activity, enhanced
dephosphorylationofHoxA10byconstitutivelyactive SHP-2
synergizes with HoxA10 overexpression to accelerate disease
progression to AML [82].
6.Perspectives
Since its discovery, tremendous progress has been made in
understanding the physiological functions of SHP-2 and its
clinical relevance to human diseases. However, there are still
numerous questions that remain to be addressed. All of the
available data support that GOF mutations in PTPN11 play
ac a u s a lr o l ei nN S ,L S ,a n dJ M M L ;h o w e v e r ,w h e t h e rt h e
contributionofPTPN11mutationstoacuteleukemiasrepre-
sents a primary eventor a second hit acquired during disease
progression is not conclusive. Moreover, upregulating the
RASpathwaymaybenecessary butnot suﬃcientforPTPN11
mutations to cause leukemias. Further studies are needed
to ﬁnd new signaling pathways and molecules disturbed
by leukemia-associated mutant SHP-2. Finally, our current
understanding is very limited regarding the role of SHP-
2 in maintaining HSC functions. Fully characterizing how
PTPN11 mutations deregulate HSC activity may provide
new insights into the pathogenesis of PTPN11 mutation-
associated acute leukemias and improve stem cell-based
therapies.
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